My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 305

    1.

    The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study.

    Heise T, Bott S, Tusek C, Stephan JA, Kawabata T, Finco-Kent D, Liu C, Krasner A.

    Diabetes Care. 2005 Sep;28(9):2161-9.PMID: 16123484 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.

    Quattrin T, Bélanger A, Bohannon NJ, Schwartz SL; Exubera Phase III Study Group.

    Diabetes Care. 2004 Nov;27(11):2622-7.PMID: 15504996 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea.

    Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M.

    Diabetes Care. 2006 Jun;29(6):1282-7.PMID: 16732009 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.

    Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I.

    Clin Ther. 2004 Dec;26(12):2084-91.PMID: 15823772 [PubMed - indexed for MEDLINE]Related articles

    5.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    6.

    Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes.

    Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, Adamson U.

    Diabetes Care. 2004 Jan;27(1):162-7.PMID: 14693983 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.

    Cernea S, Kidron M, Wohlgelernter J, Raz I.

    Clin Ther. 2005 Oct;27(10):1562-70.PMID: 16330292 [PubMed - indexed for MEDLINE]Related articles

    8.

    Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.

    Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Peña A, Muchmore DB.

    Diabetologia. 2006 May;49(5):891-9. Epub 2006 Feb 28.PMID: 16506054 [PubMed - indexed for MEDLINE]Related articles

    9.

    Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.

    Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS 2nd, Heinemann L, Batycky RP, Muchmore DB.

    Diabetes Care. 2005 Oct;28(10):2400-5.PMID: 16186270 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.

    Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR.

    Diabetes Care. 2004 Oct;27(10):2356-62.PMID: 15451900 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.

    Perera AD, Kapitza C, Nosek L, Fishman RS, Shapiro DA, Heise T, Heinemann L.

    Diabetes Care. 2002 Dec;25(12):2276-81.PMID: 12453973 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes.

    Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA.

    Diabetes Care. 2004 Jun;27(6):1318-23.PMID: 15161782 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

    Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR.

    Diabetes Care. 2003 Jan;26(1):1-8.PMID: 12502651 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

    Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.

    Ceglia L, Lau J, Pittas AG.

    Ann Intern Med. 2006 Nov 7;145(9):665-75.PMID: 17088580 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial.

    Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group.

    Diabetes Care. 2005 Jul;28(7):1630-5.PMID: 15983312 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.

    Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T.

    Diabetes Care. 2005 May;28(5):1077-82.PMID: 15855570 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

    Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR.

    Diabetes Care. 2005 May;28(5):1107-12.PMID: 15855574 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    20.

    Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes.

    Kim D, Mudaliar S, Chinnapongse S, Chu N, Boies SM, Davis T, Perera AD, Fishman RS, Shapiro DA, Henry R.

    Diabetes Care. 2003 Oct;26(10):2842-7.PMID: 14514589 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity